Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Mapping the clinical trial landscape of multiple primary lung cancer in the era of precision oncology: persistent exclusion and design limitations hamper evidence-based treatment development.Frontiers in oncology · 2025
   Review
2. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.Nature genetics · 2024
   Article
3. Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.Gut · 2022
   Article
4. In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
   Article
5. Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making.British journal of clinical pharmacology · 2019
   Review
6. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.The Journal of pathology · 2018
   Article
7. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.Gut · 2018
   Review
8. Imaging biomarker roadmap for cancer studies.Nature reviews. Clinical oncology · 2017
   Review
9. Communicating About Precision Oncology.JCO precision oncology · 2017
   Article
10. Precision medicine: the foundation of future cancer therapeutics.NPJ precision oncology · 2017
    Article
11. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.Oncotarget · 2016
    Article
12. Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.Cancer · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as